子宫内膜异位症/子宫腺肌病药物研发是否需要范式转变?
该综述检索了临床试验注册库和药物数据库,梳理了子宫内膜异位症/子宫腺肌病在研及已试验的化合物,并分析了失败试验的原因。发现仅少数完成试验发表结果,大量「新」化合物实为老药新用,动物模型不能复现人类疾病关键特征,提示药物研发创新严重枯竭。
要点
- 仅小部分已完成的子宫内膜异位症试验发表了结果
- 大量在研「新」化合物为老药新用,难以对抗纤维增殖特性
- 现有动物模型均不能复现人类子宫内膜异位症关键特征
核心结论
- 子宫内膜异位症/子宫腺肌病药物研发创新严重枯竭,失败试验的原因多不明确,当前转化模型的价值严重存疑,或需转变研究范式。
研究设计与样本
- 综述:检索ClinicalTrials.gov及汤森路透药物数据库,纳入所有已进行或正在进行临床试验、或处于开发阶段的治疗性化合物,并用试验编号在PubMed和Google检索发表状态。
- 对完成至少2年且已或未发表结果的试验,用受试治疗名称联合「endometriosis」或「adenomyosis」在PubMed检索试验启动前的临床前研究,并追溯已发表试验引用的临床前研究。
主要发现
- 尽管反复呼吁增加透明度,仅小部分已完成的子宫内膜异位症试验发表了结果。
- 大量在研「新」化合物仅为老药新用,似乎难以对抗子宫内膜异位症/子宫腺肌病的纤维增殖特性。
- 部分试验因未预见的严重副作用或试图抑制可被冗余通路代偿的靶点而失败,但许多试验在疗效上失败,提示当前模型的转化价值严重存疑。
- 所有现有子宫内膜异位症动物模型均不能复现人类疾病的关键特征。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The drug research and development (R&D) for endometriosis/adenomyosis has been painfully slow. Most completed clinical trials on endometriosis did not publish their results, and presumably failed. While few published trials did report how they foundered, the reasons why they failed are often completely unclear. Surprisingly, there has been no open discussion on why these trials failed. If the causes for these failed trials remain unelucidated, mistakes made in these failed trials may be repeated in the future. Since failure can be infinitely more instructive and educational than success, elucidating the causes for failed clinical trials may yield a treasure trove for future drug R&D. Given our growing understanding of the natural history of ectopic endometrium, it is also important to make an inventory of biologicals/compounds that are currently under development to see where we stand and whether they would stand a better chance of gaining regulatory approval than their predecessors. OBJECTIVE AND RATIONALE: We provide an overview of all compounds under clinical investigation and in development in order to assess the evolution of R&D since the last inventory, reported in 2013. We also have attempted to analyse selected failed clinical trials in the context of published translational/preclinical research and our growing understanding of the natural history of endometriotic/adenomyotic lesions, in the hope that the lessons learned will steer investigators toward the right track in future drug R&D. SEARCH METHODS: We searched ClinicalTrials.gov and a database containing information on drugs gathered daily by Thomson Reuters from a wide range of sources (e.g. patent offices, biomedical literature, congresses, symposia, meetings, company information, regulatory information) for all therapeutic compounds that have undergone or are under clinical trials, or in the developmental stage, and then searched PubMed and Google to determine their publication status using trial identifiers. For trials that were completed at least 2 years ago and have, or have not, published their results, a PubMed search was performed using the name of the therapeutic that has been tested and 'endometriosis' or 'adenomyosis' to identify published preclinical studies prior to the launch of the trial. For those published trials, the cited preclinical studies were also retrieved and scrutinized. OUTCOMES: Despite repeated calls for more transparency, only a small fraction of completed trials on endometriosis has been published. A large number of 'novel' compounds under development are simply repurposed drugs, which seem to be ill-prepared to combat the fibroproliferative nature of endometriosis/adenomyosis. This sobering picture indicates an alarming innovation 'drought' in the drug R&D front, resulting in trickling drug pipelines. Some trials foundered owing to unanticipated serious side-effects, or because attempts were made to suppress a target that can be compensated for by redundant pathways, but many failed in efficacy, indicating that the translational value of the current models is seriously questionable. All existing animal models of endometriosis do not recapitulate the key features of human conditions. WIDER IMPLICATIONS: The glaring innovation drought in drug R&D for endometriosis/adenomyosis should sound alarms to all stake-holders. The failed clinical trials in endometriosis also indicate that some past research had serious deficiencies. In light of the recent understanding of the natural history of ectopic endometrium, it is perhaps time to shift the research paradigm and revamp our research focus and priorities.
引用
- Guo SW, Groothuis PG. Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis? Hum Reprod Update. 2018. PMID: 29893860. doi:10.1093/humupd/dmy020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。